Physician profile
Amber Morrow
NPI 1821631631
$4,444.48
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $642 · 2022: $1,436 · 2023: $1,977 · 2024: $389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,301 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,300.58 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $879.14 | 2021-2024 | |
| Novo Nordisk INC | $521.19 | 2021-2024 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals Lp | $509.99 | 2021-2024 | Farxiga, Breztri |
| Lilly USA, LLC | $388.84 | 2021-2024 | Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $359.21 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $312.66 | 2022-2024 | |
| Amgen INC. | $230.21 | 2021-2024 | Evenity, Prolia, Repatha |
| Biohaven Pharmaceutical Holding Company Ltd. | $165.75 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $153.75 | 2022-2024 | Rexulti |
| Astellas Pharma US INC | $128.83 | 2023-2024 | Veozah |
| Lundbeck LLC | $105.10 | 2021-2023 | Rexulti |
| Tris Pharma INC | $97.96 | 2022-2023 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $78.91 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Exact Sciences Corporation | $69.26 | 2023-2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $58.96 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $56.67 | 2022-2023 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $47.24 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.62 | 2023 | Jardiance |
| Biohaven Pharmaceuticals, INC. | $43.37 | 2021 | |
| Idorsia Pharmaceuticals US INC | $38.07 | 2023 | Quviviq |
| Jazz Pharmaceuticals INC. | $36.94 | 2021 | |
| Mylan Specialty L.P. | $33.21 | 2022 | |
| Seqirus USA INC | $20.12 | 2022 | |
| Almatica Pharma LLC | $19.99 | 2023 | Gralise, Loreev Xr |
| Sanofi-Aventis U.S. LLC | $16.66 | 2022 | |
| Hikma Pharmaceuticals USA | $15.69 | 2021 | |
| Vistapharm, INC. | $11.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Morrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.